We are discovering novel gene therapies for the treatment of kidney diseases.

Our mission is to cure kidney diseases by discovering, developing and commercializing novel gene therapies.

There are more than 450 rare monogenic kidney diseases without a cure. In most cases, patients reach end-stage renal failure and require dialysis and a kidney transplant, which significantly affects their quality of life.

Ninevah Therapeutics (NTX) lead discovery program is an AAV-based approach for podocyte-associated genetic disorders (NTX014). Our goal is to translate NTX014 from discovery to a first-in-human trial (FIH).

NTX is building a second discovery program to deliver a gene therapy for CKD patients.

Ninevah Therapeutics was founded in Barcelona.


AAV-based Podocyte

A discovery program to develop an AAV-based platform targeting the podocytes,.

Genetics & Kidney

Genetics & Kidney
Knowledge of the primary cause of a disease is essential for understanding its mechanisms and for adequate classification, prognosis, and treatment. In the past years, multiple kidney diseases have been revealed as single-gene defects.

Several already described syndromes with a collection of symptoms due to kidney damage.

In particular, nephrotic syndrome (NS) is defined as heavy proteinuria severe enough to cause hypoalbuminemia, edema, and hypercholesterolemia.

  • The second most frequent cause of end-stage kidney disease (ESKD) in children.
  • 20% of patients become resistant to steroids (SRNS) and only ~20-30% of pediatric patients are steroid-sensitive.
  • SRNS leads to end stage renal disease (ESRD), the last stage of chronic kidney disease (CKD) in more than 50% of patients.
  • 30% of cases (or more) of SRNS are caused by mutations of genes.
  • Genetic forms of NS affects 1 to 3 per 100,000 children worldwide.

The features of nephrotic syndrome are caused by failure of the kidneys to filter waste products from the blood and remove them in urine. Signs and symptoms of this condition are excessive protein in the urine (proteinuria), increased cholesterol in the blood (hypercholesterolemia), an abnormal buildup of fluid in the abdominal cavity (ascites), and swelling (edema). Affected individuals may also have blood in the urine (hematuria), which can lead to a reduced number of red blood cells (anemia) in the body, abnormal blood clotting, or reduced amounts of certain white blood cells. Low white blood cell counts can lead to a weakened immune system and frequent infections in people with congenital nephrotic syndrome.

Children with genetic forms of nephrotic syndrome typically develop end-stage renal disease between ages 2 and 8, although with treatment, some may not have kidney failure until adolescence or early adulthood.

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition

Unfortunately, there is no specific treatment available.


Marc Ramis Castelltort, PhD

Co-founder & Interim CEO

Marc is passionate about creating novel biomedical ventures. He is a co-founder and CEO at Rejuversen AG. He is also a co-founder at Ninevah Therapeutics SL and Senolytic Therapeutics Inc. Currently, Marc is a Board member or strategic advisor at Ninevah Therapeutics, Retinset Therapeutics, Cyclomed, Gate2Brain, Cebiotex and Origen Ventures. He is a co-founder and Partner at Chasing Science, an early-stage biomedical venture builder. Marc is also a founder and Advisor at Tech & Business Innovation (TBI), an academic firm focused on knowledge exchange and corporate-academic partnerships. He also supported investments and strategic partnerships at Life Biosciences Inc. in Europe. Marc brings experience as advisor and board member for multiple organizations and as co-founder of several companies. Marc has implemented Entrepreneurs-in-Residence programs at several academic institutions such as IRB Barcelona. From 2010 to 2012, Marc was working for Isis Innovations/University of Oxford as an associate consultant in Spain and LATAM. From 2007 to 2011, Marc was working at Endor, a nanomedicine company based in Spain. During this period, he was R&D director (drug-delivery nano-systems for cancer therapy) and Business Development Director (launched several nanotechnology products to the cosmetic and textile markets). Previously, Marc also worked in the pharmaceutical environment in Novartis. He also collaborated with other research institutions such as Cancer Research UK and Boston College during his academic career. Marc gained a DPhil in Biochemistry from the University of Oxford in 2006, and a Harvard Business School PLD Program in 2011. Marc also gained a M.Sc. in Chemical Engineering in 2001 and a B.Sc. in Chemistry from IQS (Barcelona) in 2000.

Gonzalo Fernández-Miranda, PhD


Gonzalo combines a solid scientific background from his 15 years working in top research centers (CNIO, CRG and IRB Barcelona) with a passionate attitude and hands-on experience in entrepreneurship in the biotechnology sector. Since 2016, he linked his research in the laboratory with the creation of a spin-off whose main objective was to attract private investors to develop an antitumor molecule. He was selected as Project leader of the CaixaImpulse grant (2017 edition) and performed executive training from ESADE “From Science to Business Course”. He also serves as a consultant and venture builder at Chasing Science to support the development of therapeutic programs . He holds a PhD with European distinction in Molecular Biology from Universidad Autónoma de Madrid.


  • Carrer de Baldiri Reixac, 4, Barcelona, Spain